Legal & General Group
MRKR icon

Legal & General Group’s Marker Therapeutics MRKR Stock Holding History

Legal & General Group’s Portfolio MRKR Stock Details MRKR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-274
Closed -$6K – 3592
2021
Q1 		$6K Sell
274
-55
-17% -$1.26K ﹤0.01% 3461
2020
Q4 		$5K Hold
329
– – ﹤0.01% 3429
2020
Q3 		$5K Sell
329
-192
-37% -$3.5K ﹤0.01% 3379
2020
Q2 		$11K Hold
521
– – ﹤0.01% 3287
2020
Q1 		$10K Sell
521
-36
-6% -$917 ﹤0.01% 3156
2019
Q4 		$16K Buy
557
+104
+23% +$3.78K ﹤0.01% 3233
2019
Q3 		$23K Hold
453
– – ﹤0.01% 3090
2019
Q2 		$36K Buy
+453
New +$26.9K ﹤0.01% 2928

Other funds holding MRKR

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Legal & General Group's MRKR Position: Q2 2021 in Review

Legal & General Group sold out of Marker Therapeutics (MRKR) in Q2 2021, closing a stake of 274 shares — an estimated $6K sold.

Legal & General Group first reported a position in MRKR in Q2 2019 and held it in 8 quarters. The position peaked at $36K in Q2 2019. 74 funds tracked by Wall St. Rank hold MRKR as of Q2 2021.

  • Legal & General Group reported no remaining Marker Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Legal & General Group sold 274 Marker Therapeutics shares in Q2 2021, an estimated $6K.
  • Legal & General Group first reported a position in Marker Therapeutics in Q2 2019 and held it in 8 quarters.
  • Legal & General Group's Marker Therapeutics position peaked at $36K in Q2 2019.
  • 74 funds tracked by Wall St. Rank held Marker Therapeutics as of Q2 2021.

Based on Legal & General Group's 13F filing for Q2 2021, filed 12 Aug 2021.